| I-021 Enrique José Bandín Vilar OPTIMIZATION OF THE DOSAGE REGIMEN OF LONG-ACTING INJECTABLE ARIPIPRAZOLE THROUGH MONTE CARLO SIMULATIONS Wednesday 10:20-11:50 |
| I-024 Carla Bastida Fernández Predictive performance of published meropenem population pharmacokinetic models in critically ill adult patients. Wednesday 10:20-11:50 |
| I-026 Emily Behrens External evaluation of pharmacometric models of moxifloxacin for Bayesian forecasting in the treatment of tuberculosis Wednesday 10:20-11:50 |
| I-031 Jan Berkhout A model-based approach to predict SC administration and free target dynamics for monoclonal antibodies using PK and total target measurements after IV administration Wednesday 10:20-11:50 |
| I-040 Jordan Brooks Steps Toward Model-Informed Precision Dosing of PEG-Asparaginase in Children and Young Adults Wednesday 10:20-11:50 |
| I-104 Aaqilah Fataar Using Bayesian Modelling to Evaluate the Effect of a Neonatal Vancomycin Loading Dose on Therapeutic Target Attainment in a Low-Middle Income Country Wednesday 10:20-11:50 |
| II-008 Janice Goh A model-informed framework for prioritizing pharmacogenomic drug-gene interactions in an Asian context for chemotherapy Wednesday 15:20-16:50 |
| II-010 Juan Guillermo Gonzalez Maffe A Bayesian (P)K-TTE model to support early dose escalation decisions in phase 1 Oncology studies Wednesday 15:20-16:50 |
| II-032 Astrid Heida Model-informed dose optimization of mycophenolic acid in pediatric renal transplant patients Wednesday 15:20-16:50 |
| II-061 Xu Jiang Population pharmacokinetic and pharmacodynamic analysis of granulocyte colony-stimulating factor (G-CSF) to optimize dose and timing for harvesting CD34+ cells Wednesday 15:20-16:50 |
| II-074 Anisa Khan Population pharmacokinetics of cenobamate and dose rationale for its use in paediatric patients affected by focal onset and primary generalized tonic-clonic seizures. Wednesday 15:20-16:50 |
| II-081 Sjoerd Koopman A revised population pharmacokinetic model for recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin Wednesday 15:20-16:50 |
| II-099 Antonia Leonhardt Towards MIPD of Linezolid: External Evaluation of Population Pharmacokinetic Models Wednesday 15:20-16:50 |
| III-001 Nicolas Luyckx Model-Informed Precision Dosing of Tacrolimus in Lung Transplantation Early After Surgery Using Model-Predictive Control in the tdmore Framework Thursday 09:50-11:20 |
| III-005 SOPHIE MAGREAULT What clindamycin dose for which administration route in case of combination with rifampicin? Thursday 09:50-11:20 |
| III-046 XU NUO Population Pharmacokinetics and Safety Assessment of Rifapentine in Chinese Children to Inform Dosing Recommendations for Latent Tuberculosis Infection Thursday 09:50-11:20 |
| III-092 Camille Riff Pharmacokinetics of inhaled AZD4604 supports lack of JAK1 systemic activity at therapeutic dose Thursday 09:50-11:20 |
| IV-011 Victor Sokolov Quantitative Systems Pharmacology Model of Type 1 IFN-mediated Inflammation in Systemic Lupus Erythematosus Thursday 15:00-16:30 |
| IV-027 Jérémie Tachet Population pharmacokinetic modelling of oral ruxolitinib: a real-world prospective observational study Thursday 15:00-16:30 |
| IV-045 Quan Truong Underdosing imipenem in patients with renal insufficiency: global clinical data-driven pharmacokinetic/pharmacodynamic study Thursday 15:00-16:30 |
| IV-052 Stefan van den Berg Pharmacokinetic model-informed precision dosing of natalizumab in Multiple Sclerosis Thursday 15:00-16:30 |
| IV-060 Erno van Schaick Population Pharmacokinetic Modeling of Leriglitazone in Healthy Volunteers and Patients with Neuro-degenerative Disorders – Exploring dosing schedules in children with adrenoleukodystrophy via simulations Thursday 15:00-16:30 |
| IV-082 Franz Weber Successful validation of a model-informed precision dosing instrument for meropenem in critically ill patients, the DoseCalculator, against NONMEM® Thursday 15:00-16:30 |
| IV-085 Ella Widigson Model-derived PK target profile of ustekinumab therapeutic thresholds in inflammatory bowel diseases to guide precision dosing Thursday 15:00-16:30 |
